4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Osteomyelitis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 46 ongoing clinical trials involving Osteomyelitis
Of the 46 trials,22 trials are in Phase IV
Furthermore, 15 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Osteomyelitis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Osteomyelitis, an infectious disease. The largest number of ongoing clinical trials for Osteomyelitis is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Osteomyelitis-related drug trials.

Osteomyelitis related clinical trial sponsor

Debiopharm International SA, Seattle Children's Hospital, Nabriva Therapeutics Plc, The United Laboratories International Holdings Ltd, and Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd are among the notable clinical trial sponsors involved in Osteomyelitis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Osteomyelitis

Amoxicillin and Clavulanate potassium (Augmentin, Augmentin Trio forte, Clavulin, Augmentin Duo, Augmentin ES, Clavamox, Augmentin Forte, Augmentin Duo Forte, Agumentin P), Cefoperazone Sodium and Sulbactam sodium (Sulperazone, Magnex, Magnex Forte), and Ceftriaxone sodium (Rocephin, Rocefin) are among the key marketed drugs involving Osteomyelitis.

Amoxicillin and Clavulanate potassium (Augmentin, Augmentin Trio forte, Clavulin, Augmentin Duo, Augmentin ES, Clavamox, Augmentin Forte, Augmentin Duo Forte, Agumentin P) is fixed dose combination drug, is an antibacterial agent. It functions via Beta Lactamase (EC 3.5.2.6) Inhibitor; Penicillin Binding Protein (PBP) Inhibitor mechanism of action. It is formulated as tablet, film coated tablets, chewable tablets, powder for suspension and powder for solution for oral route of administration and powder for solution for intravenous route of administration. Amoxicillin and Clavulanate potassium is marketed for the treatment of Osteomyelitis and several other indications including Urinary Tract Infections, Respiratory Tract Infections, Bacillary Dysentery (Shigellosis), Acute Bronchitis, Bacterial Pneumonia, Pharyngitis, Gonorrhea, Laryngitis, Abscess, Bacteremia, Cellulitis, Upper Respiratory Tract Infections, Chronic Bronchitis, Lower Respiratory Tract Infections, Community Acquired Pneumonia, Urethritis, Otitis Media, Tonsillitis, and Bronchitis. Amoxicillin and Clavulanate potassium was first approved in 1982 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by several pharma giants including GlaxoSmithKline Plc, Coland Holdings Limited, and Aspen Pharmacare Holdings Ltd.

Cefoperazone Sodium and Sulbactam sodium (Sulperazone, Magnex, Magnex Forte) is a fixed combination of cephalosporin antibiotic and beta-lactamase inhibitor. It functions via Beta Lactamase (EC 3.5.2.6) Inhibitor; Penicillin Binding Protein (PBP) Inhibitor mechanism of action. It is formulated as injectable powder for solution for intravenous route of administration. Cefoperazone Sodium and Sulbactam sodium is marketed for the treatment of Osteomyelitis and several other indications including Urinary Tract Infections, Bacterial Conjunctivitis, Cholangitis, Cholecystitis, Pancreatitis, Acute Bronchitis, Bacterial Pneumonia, Pharyngitis, Gonorrhea, Bacterial (Pyogenic) Meningitis, Laryngitis, Abdominal Abscess, Abscess, Liver Abscess, Endometriosis, and Tonsillitis. Cefoperazone Sodium and Sulbactam sodium was first approved in 1986 and is marketed in China, India, Indonesia and Japan by Pfizer Inc.